Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer

Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a 5-year overall survival (OS) rate of approximately 12%. More than 90% of PDAC patients harbor oncogenic mutations in the Kirsten rat sarcoma viral homolog (KRAS) gene. MRTX1133 (MRTX), a novel inhibitor of KRAS G12D...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey Xiao, Joshua Kim, Brandon Park, David J. Baylink, Cedric Kwon, Victoria Tran, Scott Lee, Kevin Codorniz, Laren Tan, Pamela Lobo Moreno, Amy Schill-Depew, Saied Mirshahidi, David De Semir, Diana Hanna, Kiran Naqvi, Huynh Cao, Chien-Shing Chen, Joanne Xiu, Heinz-Josef Lenz, Hamid Mirshahidi, Mark E Reeves, Yi Xu
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Experimental Hematology & Oncology
Subjects:
PDAC
NFκB2
KRAS
MRTX1133
Bedaquiline
Helicase
Online Access:https://doi.org/10.1186/s40164-025-00669-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40164-025-00669-w

Similar Items